Odel (B). IL-12 treatment significantly reduces tumor growth following cyclophosphamide treatment in late stage tumor models. In the EL4 tumor model, treatment with IL-12 pre-post or IL-12 post-only significantly reduced tumor growth (%T/C < 50%), as compared to both the G-CSF vehicle control groups at the end point of tumor growth assessments. In the Lewis lung cancer model, the IL-12 pre-post and IL-12 pre-only treatment groups yielded a significant reduction in tumor growth (%T/C < 50%), as compared to both the G-CSF and vehicle control groups at the end point of tumor growth assessments. These tumor models represent a late stage cancers, as compared with the models used for the radiation studies because tumors were apparent at the start of the treatments consisting of cyclophosphamide and cytokine therapy. In the case of the lymphoma model, therapy was initiated when the tumors were very large (about 500 mm).<p><b>Copyright information:</b></p><p>Taken from "Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice"</p><p>http://www.translational-medicine.com/content/6/1/26</p><p>Journal of Translational Medicine 2008;6():26-26.</p><p>Published online 19 May 2008</p><p>PMCID:PMC2424034.</p><p></p
